Search results
Growing evidence suggests that pharmacotherapy may be beneficial for some patients with binge eating disorder (BED), an eating disorder characterized by repetitive episodes of uncontrollable consumption of abnormally large amounts of food without inappropriate weight loss behaviors.
- Current and Emerging Drug Treatments for Binge Eating Disorder
A total of 47% in the drug condition versus 21% in the...
- Treatment of Binge-Eating Disorder Across the Lifespan: An Updated ...
Summary. Research on BED treatment continues to grow, though...
- Pharmacological treatment of binge eating disorder: update ... - PubMed
The evidence base regarding pharmacotherapy for BED remains...
- Current and Emerging Drug Treatments for Binge Eating Disorder
A total of 47% in the drug condition versus 21% in the placebo condition achieved remission (p=.07). Weight Loss Mean BMI decreased from 41.1 to 40.9 in the drug condition versus an increase from 34.2 to 35.7 in the placebo condition, which indicated a significantly greater advantage for the citalopram group (p<.001).
Summary. Research on BED treatment continues to grow, though critical questions must be answered to improve treatment efficacy across the lifespan. Keywords: Binge-eating disorder, Treatment, Psychotherapy, Pharmacotherapy, Review, Efficacy. Introduction.
The evidence base regarding pharmacotherapy for BED remains limited, although this year the FDA approved the first medication (i.e., lisdexamfetamine dimesylate; LDX) specifically for moderate-to-severe BED. Data from RCTs suggest certain medications are superior to placebos for reducing binge eatin ….
Growing evidence suggests that pharmacotherapy may be beneficial for some patients with binge eating disorder (BED), an eating disorder characterized by repetitive episodes of uncontrollable consumption of abnormally large amounts of food without inappropriate weight loss behaviors.
7 sty 2022 · Binge-eating disorder (BED) is the commonest eating disorder and an important causal factor in obesity. Lisdexamfetamine is the only approved pharmacological treatment.
Pharmacotherapy. We located 22 prospective, randomized, placebo- controlled pharmacotherapy studies of BED or closely related syndromes (Tables 2–4). Most trials were short-term (6–16 weeks) and all were conducted in adults who were actively binge eating. The majority of studies excluded patients with serious or.
